Whipplewood Advisors LLC Trims Stock Position in Stryker Corporation $SYK

Whipplewood Advisors LLC lessened its holdings in shares of Stryker Corporation (NYSE:SYK) by 70.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 466 shares of the medical technology company’s stock after selling 1,105 shares during the period. Whipplewood Advisors LLC’s holdings in Stryker were worth $184,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in SYK. Brighton Jones LLC raised its holdings in shares of Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Stryker by 16.4% during the first quarter. GAMMA Investing LLC now owns 5,574 shares of the medical technology company’s stock worth $2,075,000 after purchasing an additional 785 shares during the last quarter. Creative Financial Designs Inc. ADV raised its holdings in shares of Stryker by 11.1% during the first quarter. Creative Financial Designs Inc. ADV now owns 442 shares of the medical technology company’s stock worth $165,000 after purchasing an additional 44 shares during the last quarter. Perpetual Ltd raised its holdings in shares of Stryker by 28.8% during the first quarter. Perpetual Ltd now owns 1,234 shares of the medical technology company’s stock worth $459,000 after purchasing an additional 276 shares during the last quarter. Finally, Jaffetilchin Investment Partners LLC purchased a new position in shares of Stryker during the first quarter worth $212,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

NYSE:SYK opened at $381.86 on Monday. The company’s 50-day moving average price is $379.84 and its 200-day moving average price is $380.14. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The company has a market cap of $145.99 billion, a P/E ratio of 50.58, a P/E/G ratio of 2.75 and a beta of 0.94. Stryker Corporation has a twelve month low of $329.16 and a twelve month high of $406.19.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.07 by $0.06. The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period last year, the firm posted $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, sell-side analysts forecast that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. Stryker’s payout ratio is 44.50%.

Insider Transactions at Stryker

In other Stryker news, insider Viju Menon sold 500 shares of Stryker stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the transaction, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.20% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research firms recently commented on SYK. UBS Group set a $408.00 price target on shares of Stryker in a research report on Monday, October 13th. BTIG Research raised their price target on shares of Stryker from $407.00 to $408.00 and gave the company a “buy” rating in a research report on Monday, October 13th. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Needham & Company LLC raised their price target on shares of Stryker from $442.00 to $448.00 and gave the company a “buy” rating in a research report on Friday, August 1st. Finally, Barclays raised their price target on shares of Stryker from $443.00 to $453.00 and gave the company an “overweight” rating in a research report on Wednesday. Fifteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $432.24.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.